IRONWOOD PHARMACEUTICALS INC

IRWD

NASDAQBiotechnology🇺🇸North America

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

None scheduled

Drug Pipeline

Drug Name	Phase	Indication	Designations
IW-3718	Phase 3	Gastroesophageal Reflux Disease (GERD)	-
Matching Placebo	Phase 3	Chronic Constipation	-
Linaclotide or Matching Placebo	Phase 3	Irritable Bowel Syndrome With Constipation	-
Placebo	Phase 3	Irritable Bowel Syndrome Characterized by Constipation	-
PPI	Phase 2	Gastroesophageal Reflux Disease	-
MD-7246	Phase 2	Irritable Bowel Syndrome With Diarrhea (IBS-D)	-
MD-1100 Acetate	Phase 2	Constipation	-
Linaclotide	Phase 2	Irritable Bowel Syndrome With Constipation	-
IW-9179	Phase 2	Diabetic Gastroparesis	-
IW-6118	Phase 2	Healthy	-
MD-0727	Phase 2	Hypercholesterolemia	-
Linaclotide Acetate	Phase 2	Irritable Bowel Syndrome With Constipation	-

Catalyst Timeline

0 upcoming, 0 past

No catalysts found.

Regulatory Approvals

IRWD News